Compare DexCom, Inc. (DXCM) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Innovative Industrial Properties Inc — how do they compare? DexCom, Inc. trades at $78.42 (market cap $28.06B), while Innovative Industrial Properties Inc trades at $64.97 (market cap $1.84B). The key difference: DexCom, Inc. is far larger — about 15.3× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.95% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | IIPR | |
|---|---|---|
Market Cap | $28.06B | $1.84B |
Sector | Health | Real Estate |
52-Week High | $89.53 | $64.44 |
52-Week Low | $54.84 | $44.58 |
Enterprise Value | $27.03B | $2.23B |
Dividend Yield | — | 11.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Innovative Industrial Properties (IIPR) trades at $63.83, showing modest daily gains. The technical outlook is bullish based on moving averages, with key support at $61-63 and resistance at $64-66. Fundamentally, the REIT maintains strong gross margins above 88% and a reasonable P/E of 16.22, though revenue declined to $266M in 2025. Recent news highlights successful debt management, including repaying $282M in senior notes and issuing new exchangeable notes, alongside a declared $1.90 quarterly dividend.
Outlook: IIPR presents a high-yield opportunity with a 13% dividend yield, supported by a strengthened balance sheet and potential tailwinds from cannabis rescheduling. Risks include tenant credit quality in the cannabis sector, revenue pressure, and negative cash flow trends. Analyst consensus leans cautious with 36% buy ratings versus 55% hold, suggesting a wait-and-see approach despite the attractive yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
